Duration of Dual Antiplatelet Therapy in the Post-Acute Coronary Syndrome Patient

Area of Science:

• Cardiology
• Pharmacology

Background:

• Current guidelines recommend 12 months of dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor post-acute coronary syndrome (ACS).
• The risk of recurrent ischemic events persists beyond 12 months, leading to debate on extending DAPT duration.
• Optimal DAPT duration in specific patient populations remains an area of active investigation.

Purpose of the Study:

• To review and investigate the optimal duration of dual antiplatelet therapy for patients following acute coronary syndrome.
• To analyze the benefits and risks associated with extended DAPT in post-ACS patients.

Main Methods:

• This is a review article, synthesizing existing literature and clinical trial data.
• The review focuses on evaluating the balance between anti-ischemic benefits and bleeding risks.
• No new clinical data was generated; the study is based on secondary data analysis.

Main Results:

• Extended DAPT is associated with an increased risk of bleeding complications.
• The anti-ischemic benefits of prolonged DAPT must be weighed against these bleeding risks.
• Individualized risk assessment is crucial for determining optimal treatment duration.

Conclusions:

• Optimal duration of dual antiplatelet therapy post-ACS is not one-size-fits-all.
• Treatment decisions must be individualized based on a thorough assessment of patient-specific ischemic and bleeding risk factors.
• Tailoring DAPT duration ensures maximizing benefits while minimizing harm.